Sherbrooke, Québec — September 17, 2025 — Leads & Copy — TATUM bioscience announced the publication of new research demonstrating strong antitumor activity from its bioengineered multimodal nanofilaments. The study, published in the Journal for Immunotherapy of Cancer (JITC), details how the therapy exposes cancer cells and orchestrates an immune response that eradicates tumors.
TATUM’s innovative nanofilament-directed immunotherapy overcomes cancer’s ability to hide from the immune system, said Jean-François Millau, Ph.D., co-founder and CEO. The drug candidate, TAT003, achieves a coordinated immune response against tumor cells.
TAT003 combines checkpoint blockade, innate activation, and T cell stimulation to drive the immune system’s antitumor response. Anti–PD-L1 single-chain antibody fragments bind to tumor cells, a TLR9 agonist activates macrophages, and IL-2 molecules stimulate T cells.
The antitumor response triggered by TAT003 nanofilament immunotherapy was both systemic and durable in animal models, said Kevin Neil, Ph.D., co-founder and Chief Scientific Officer. Replicating these results in patients is the company’s goal as it moves toward clinical development.
TATUM’s engineered nanofilaments offer distinct advantages over other therapeutic strategies. TAT003 elicits a vaccine-like effect without the complexity and cost of individualized neoantigen vaccines, according to Dr. Neil.
TATUM bioscience is currently raising funds to accelerate development and bring TAT003 into clinical trials.
About TATUM bioscience
TATUM bioscience is a preclinical biotechnology company in Sherbrooke, Québec, Canada, advancing next-generation immunotherapies to treat life-altering diseases including cancer.
Contact: Jean-François Millau, Ph.D.
